38 results about "Thrombo embolism" patented technology

The invention discloses a prediction model system for multiple myeloma venous thromboembolism, and the system comprises a data obtaining module which obtains detection data including baseline data; the data category imbalance processing module is used for performing category imbalance processing according to the baseline data to obtain sample data; the data variable screening processing module is used for carrying out variable screening according to the sample data to obtain characteristic variable data; and the data visualization processing module is used for determining the weight of each variable based on proportional risk regression according to the characteristic variable data, incorporating the weight into a preliminary screening variable, segmenting continuous variables, establishing a point value conversion system, calculating a total score and corresponding to a risk probability, and constructing a data visualization chart. The invention discloses a prediction model system for multiple myeloma venous thromboembolism, a storage medium and a use method, and aims to greatly improve the cross-metal transmission rate of ultrasonic signals and improve the accuracy, stability, convenience and practicability of risk early warning.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

The invention relates to the technical field of health monitoring, in particular to venous thromboembolism monitoring equipment which comprises an evaluation module used for providing an evaluation scale, collecting filling information of a patient and generating a risk level evaluation result; the behavior guidance module is used for generating corresponding guidance suggestions based on the risk level assessment result, so that the patient can be protected according to the guidance suggestions; the monitoring module is used for collecting monitoring data in the protection process of the patient according to the guidance suggestions, and the monitoring data comprise leg circumference data, pain feeling data, skin color data, body temperature data, limb swelling data and pulmonary embolism expression data; and the early warning module is used for generating early warning information based on the monitoring data, and sending the early warning information to related medical personnel, so that manual monitoring is replaced by the monitoring equipment, the self-protection consciousness of the patient can be autonomously stimulated, the monitoring effect is improved, and the morbidity of venous thromboembolism is reduced.

This invention discloses a magnetic embolism protection device and system, belonging to the field of medical device technology. It includes a catheter and an umbrella-shaped filter assembly disposed on the distal outer wall of the catheter. A permanent magnet is disposed within the catheter to cooperate in opening and closing the filter assembly. The catheter has a first cavity, a second cavity, and a guidewire cavity along its length. The first cavity is located near the inner wall of the catheter, while the second and guidewire cavities are located side-by-side within the catheter. The distal ends of the first and second cavities are interconnected through a connecting hole. The permanent magnet is placed in the middle of the first cavity, and a first hole is located at the proximal end of the catheter, communicating with the first cavity. By pressurizing the first cavity, the permanent magnet is displaced, further causing the unfolding and opening rods to expand and contract magnetically. The size of the umbrella opening can be controlled to adapt to blood vessels of different inner diameters. It is highly adaptable, structurally stable, and easy to control, effectively intercepting free thrombi, reducing the probability of thromboembolism, and improving the success rate of surgery.

The present invention relates to co-crystals of a compound of formula (I) in which the co-former molecule is succinic acid or citric acid, processes for preparing the co-crystals, pharmaceutical compositions thereof, and methods of treating or preventing thromboembolic disorders using the co-crystals.

The present invention relates to co-crystals of a compound of formula (I) in which the co-former molecule is succinic acid or citric acid, processes for preparing the co-crystals, pharmaceutical compositions thereof, and methods of treating or preventing thromboembolic disorders using the co-crystals.

A method for the treatment of thromboembolism comprising administering a thrombolytic agent directly to the thromboembolism in the presence of ultrasound. The total dose of thrombolytic agent administered is between 1 and 12 mg and the time over which the total dose is delivered is less than 15 hours.

Described are combined oral contraceptive compositions with reduced cardiovascular effects and methods using them. In some embodiments, the methods relate to contraceptive methods or methods for treating dysmenorrhea with reduced cardiovascular effects, such as reduced venous thromboembolism (VTE) risk. The methods comprise administering to a female subject an effective amount of an estetrol component and a progestogenic component. The methods enjoy a favourable profile for thromboembolism compared to currently available methods which employs contraceptives from the so-called second, third or fourth generation.

The invention provides a thrombus prevention method and system based on digital clinical precise execution, and relates to the technical field of digital medical treatment, and the method comprises the steps: obtaining clinical data of a patient, and determining a thromboembolism risk level, a bleeding risk level and a mechanical prevention taboo state of the patient based on a preset rule; based on the combined state of the three evaluation results, generating a thrombus prevention measure scheme for the patient through a preset prevention strategy decision rule; monitoring clinical data changes in the hospitalization process of the patient in real time, when it is detected that the risk level or the taboo state is changed, comparing the consistency of a current execution scheme with a scheme regenerated based on the changed state, and if the current execution scheme is not consistent with the scheme regenerated based on the changed state, generating preventive measure adjustment reminding information; and pushing the scheme or the adjustment prompt to a clinical medical care terminal. According to the invention, intelligent decision and dynamic adjustment of thrombus prevention can be realized, the accuracy and timeliness of prevention measures are improved, and medical risks are reduced.

The present disclosure provides pharmaceutical compositions comprising an anticoagulant and pyruvic acid. Also provided are dosage forms comprising the pharmaceutical composition and methods for treating a thromboembolic disorder in a patient in need thereof, reducing the reoccurrence of a deep vein thrombosis or a pulmonary embolism in a patient in need thereof, preventing a venous thromboembolism (VTE) in an acutely ill patient, reducing the risk of a major cardiovascular event in a patient with coronary artery disease in a patient in need thereof, method for reducing the risk of a major thrombotic vascular event in a patient with peripheral artery disease (PAD), treating VTE or reducing the risk of reoccurrence of VTE in a pediatric patient in need thereof, thromboprophylaxis in a patient with congenital heart disease after a Fontan procedure, treating atherosclerosis, myocardial infarct, pulmonary embolism or deep venous thrombosis in a patient in need thereof, or preventing one or more thromboembolic or hemorrhagic events in a patient with atrial fibrillation by comprising administering the pharmaceutical composition or transdermal patch described herein to the patient.

The invention relates to a venous thromboembolism knowledge base generation method and a storage medium. The method comprises the following steps that a big data acquisition layer in a hospital acquires venous thromboembolism data; the big data preprocessing and feature engineering layer performs cross-domain data standardization processing on the acquired venous thromboembolism data; the AI large model intelligent analysis layer analyzes the incidence relation of genetic variation-image features-clinical indexes through a VTE special large model constructed based on a Transform architecture in combination with graph neural network cross-modal knowledge reasoning, and mines a nonlinear mode of thrombus load and pulmonary embolism risk; the dynamic knowledge base generation layer constructs a VTE knowledge graph by using a graph database, and automatically updates the specific knowledge and timeliness knowledge of the carved department. Complex knowledge association in the VTE field is captured through an AI large model, and analysis of nonlinear relations and cross-domain features is enhanced.

Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and / or preventing thromboembolism and bleeding or clotting disorders. Also provided herein are methods for inhibiting thrombin in a cell using the compounds and compositions described herein.

The present invention discloses a traditional Chinese medicine composition and its use in treating pulmonary thromboembolism. The traditional Chinese medicine composition is prepared from the following raw materials: raw astragalus, whole angelica, herb agrimony, notoginseng powder, madder, red peony root, and dried tangerine peel. The traditional Chinese medicine composition of the present invention utilizes the inherent characteristics of each component raw material, rationally formulates the formula, and scientifically proportions the formula to achieve optimal synergistic efficacy. The traditional Chinese medicine composition has a definite therapeutic effect and has a good effect of reducing the incidence of bleeding during the anticoagulation process in patients with pulmonary thromboembolism. It also has low toxicity and high safety, and can improve the efficacy of anticoagulation treatment for pulmonary thromboembolism. The present invention makes up for the current shortage of traditional Chinese medicine prescriptions for pulmonary thromboembolism, and has the characteristics of a wide source of raw materials, a high safety factor, a small dosage, and a dosage form that meets clinical needs.

A kit comprising a predetermined amount of tissue factor and phospholipids in a container; a predetermined amount of the tissue factor, phospholipids and activated protein C in a second container; and a container comprising a test solution; uses of the kit; and methods for predicting the risk of pulmonary thromboembolism.

An actuated telescoping system for navigation within a vascular lumen and thrombectomy of a thrombus. The system includes a tubular catheter member having an open distal end defining a catheter lumen, a vacuum source, a rotational drive system, a flexible shaft having a channel coupled to the rotational drive system for rotational movement in response thereto, and an optional guidewire selectively inserted at least partially within the flexible shaft. The flexible shaft is at least partially disposed within the tubular catheter member configured for uncoupled rotational and translational motion therein and to optionally define a corkscrew motion in response to rotational driving force by the drive system that results in formation of hydrodynamic vortices within the catheter lumen. The telescoping system can be capable of reversibly transitioning between navigation and thrombectomy modes by differentially disposing and actuating the components and enable faster, more efficient and simpler removal of thromboembolic material.

The present application relates to the technical field of molecular diagnosis and genotyping, and particularly relates to a VTE high-risk individual identification multiplex isothermal amplification detection method and a VTE high-risk individual identification multiplex isothermal amplification detection kit, a 4-7 SNP site detection panel containing SERPINC1 antithrombin deficiency variation, PROC protein C defect hotspot (p.Arg189Trp) and at least one SNP site in MTHFR, PAI-1, FGG and ABO is constructed; an allele-specific forward primer pair with a 3' end plus the second or third artificial mismatch double-mismatch anchoring structure, a universal reverse primer and a tetrahydrofuran site probe are designed for each SNP site; a risk stratification result is output by using an OR value weighted scoring model of a Chinese population cohort, the detection is rapid, single-tube multiplex, sample consumption is low, zero-instrument optional, and is suitable for rapid screening of genetic risk of venous thromboembolism in primary medical institutions of Chinese population.

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early stages by cardiologists remain a challenge. Here, the inventors have measured baseline sTREM-1 (triggering receptor expressed on myeloid cells-1) in 10,000 initially healthy participants without prevalent cardiovascular disease (CVD) from the Paris Prospective Study 3 (PPS3). They have quantified the association and predictive value of baseline sTREM-1 for incident CVD events over 10 years of follow-up. The analysis reveals strong, significant and independent association with incident CVD events combined and its subtypes (coronary heart disease, stroke, peripheral artery diseases, and heart failure). Furthermore, adding sTREM-1 to existing risk prediction algorithms such as SCORE2 or the US pooled risk equation improved the discrimination capacity of these models in a significant and more importantly in a clinically meaningful manner, including among those at moderate CVD risk. Furthermore, the inventors have examined CVD events such as aneurysm, arrythmias and thromboembolic events. Given the ongoing development of pharmacological molecules blocking blood sTREM-1, the inventors believe these findings support future intervention trials testing to which extent sTREM-1 could be a relevant target for the primary prevention of CVD in the general population.

The present invention relates to a pyrazol[3,4 c] pyridine derivative, preparation method and use in medicine thereof. Specifically, the present invention relates to a novel pyrazol[3,4 c] pyridine derivative, preparation method thereof and a pharmaceutical composition comprising the derivative and use thereof as a therapeutic agent, especially their use as Xa factor inhibitors and in the preparation of drugs for treating diseases like thromboembolism.

The invention discloses a medicine for treating atrial fibrillation in an acute exacerbation stage of a chronic obstructive pulmonary disease and a preparation method of the medicine. The medicine is prepared from raw rhizoma coptidis, raw fructus gardeniae, lophatherum gracile, radix ophiopogonis, radix rehmanniae recen, lily, codonopsis pilosula, radix salviae miltiorrhizae, moutan bark, radix paeoniae rubra, semen boitae, spina date seeds, poria with hostwood and raw liquorice. The traditional Chinese medicine composition has the effects of clearing away heart fire and nourishing heart yin, has the effects of cooling and activating blood and clearing away heart fire and tranquilizing mind, and is suitable for atrial fibrillation in the acute exacerbation stage of chronic obstructive pulmonary disease, assisting in controlling the ventricular rate, preventing and treating thromboembolism and promoting the atrial fibrillation rhythm to be converted into sinus normal rhythm.

Provided herein are compositions, systems, kits, and methods for treating a patient with a thromboembolism by administering nanoconjugates comprising nanoparticles encapsulating and / or conjugated to: i) tissue-type plasminogen activator (tPA), and ii) at least one antioxidant enzyme selected from the group consisting of: superoxide dismutase, glutathione peroxidase, glutathione reductase, and a catalase.

The invention belongs to the technical field of biological medicine, and discloses application of an active substance in preparation of a VKOR inhibitor and / or a vitamin K antagonist and an anticoagulant drug. The invention provides application of an active substance shown in a formula (1) or pharmaceutically acceptable salt thereof in preparation of a vitamin K epoxide reductase inhibitor. The active substance has VKOR inhibitory activity, can prevent liver from synthesizing blood coagulation factors and activating anticoagulant factors by blocking reduction of oxidized vitamin K and inhibiting circulation of vitamin K, has potential anticoagulant activity, and has the advantages of mild anticoagulant effect, low probability of occurrence of adverse hemorrhage events, good anticoagulant effect, high safety and the like. The compound has a good application prospect in preparation of anticoagulants and / or medicines for treating thromboembolic diseases.

A medical device is provided in which one or both ends of the device encourage the formation of tissue across substantially the entire area of the respective end that is exposed to the blood flow for reducing the risk of a thrombotic embolism. The medical device includes a tubular structure having at least one expanded volume portion and a tapered transition portion. The tubular structure may be made through the braiding of a number of strands, and a first end feature may be used to secure the proximal strand ends. The proximal strand ends may be secured via the proximal end of the first end feature, such that the tapered transition portion is formed over the circumferential surface of the first end feature, and only a proximal end surface (or a portion of the proximal end surface) of the first end feature is exposed to the path of flowing blood.

The invention belongs to the technical field of immunodetection analysis, and discloses a kit for quantitative detection of a thrombin-antithrombin III compound and a preparation method of the kit. The kit comprises a magnetic bead working solution, an acridinium ester marker working solution, a biotin marker working solution, a TAT calibrator and a TAT quality control product, and quantitative detection of TAT is realized by combining a double-antibody sandwich method with a chemiluminescence technology. The method overcomes the defects that an existing fluorescence immunoassay method is low in repeatability, and an immunoturbidimetry method is high in requirement for specimens and limited in low-concentration detection capacity, and has the advantages of being high in specificity, sensitivity and accuracy and easy, convenient and rapid to operate. The method can be used for clinical auxiliary diagnosis of thrombogenic diseases such as disseminated intravascular coagulation (DIC) and venous thromboembolism (VTE), and provides a basis for blood coagulation state evaluation and clinical decision making.

The present invention relates to novel sustained release formulation of milvexian, which are useful for the treatment or prevention of thromboembolic events. The invention is particularly suitable for once-a-day administration of milvexian, releasing a therapeutically effective amount of the milvexian over an extended time.

Disclosed are compounds of Formula (I) to (VIII):or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

The present application relates to the field of medical diagnosis, and specifically provides a risk assessment model for venous thromboembolism (VTE) of Chinese population and application thereof. The model is based on the genetic characteristics of Chinese population, and contains 15 genetic variables (SNPs) related to the pathophysiological mechanism of VTE, covering five aspects of anticoagulation system, coagulation system, fibrinolysis system, platelet system and vascular endothelial system. The model assesses the genetic risk of VTE of patients by calculating VTE-PRS-15 value, and determines the comprehensive risk grade of patients in combination with Caprini clinical assessment scale. The present application also provides a corresponding genetic polymorphism detection kit. According to clinical data verification, the model improves the accuracy and practicability of VTE risk assessment.

A medical device is provided in which one or both ends of the device encourage the formation of tissue across substantially the entire area of the respective end that is exposed to the blood flow for reducing the risk of a thrombotic embolism. The medical device includes a tubular structure having at least one expanded volume portion and a tapered transition portion. The tubular structure may be made through the braiding of a number of strands, and a first end feature may be used to secure the proximal strand ends. The proximal strand ends may be secured via the proximal end of the first end feature, such that the tapered transition portion is formed over the circumferential surface of the first end feature, and only a proximal end surface (or a portion of the proximal end surface) of the first end feature is exposed to the path of flowing blood.

The invention relates to the field of medical diagnosis, in particular to a risk assessment model suitable for venous thromboembolism (VTE) of Chinese population and application of the risk assessment model. The model is based on genetic characteristics of Chinese population, comprises 15 genetic variables (SNP) related to a VTE pathophysiology mechanism, and covers five aspects of an anticoagulation system, a blood coagulation system, a fibrinolytic system, a platelet system and a vascular endothelial system. According to the model, the VTE genetic risk of a patient is evaluated by calculating a VTE-PRS-15 value, and the comprehensive risk level of the patient is determined by combining with a Caprini clinical evaluation scale. The invention also provides a corresponding gene polymorphism detection kit. Clinical data verifies that the model improves the accuracy and practicability of VTE risk assessment.